AGA Nanotech Tackles Biofilms in Bone Infections Through MSK Innovation Accelerator
Participating in a six-month programme, AGA Nanotech will advance Battlestar™ for osteomyelitis, supported by clinical and industry expertise to AMR in musculoskeletal infections.AGA Nanotech is proud to announce its selection for the Musculoskeletal (MSK) Innovation Accelerator, powered by Orthopaedic Research UK. This prestigious programme is designed to scale early-stage MSK ventures by providing an intensive six-month learning journey that includes entrepreneurship training, masterclasses, and access to industry expertise.
Selected following a rigorous panel interview conducted by experts from the Imperial MedTech Superconnector and ORUK, AGA Nanotech’s CEO Harsha Siani is set to lead the development of Battlestar™ for treating osteomyelitis and joint and bone infections.
The programme includes a 3-day bootcamp held on November 12–14, which covered critical topics such as Investment Readiness, Leadership, Innovating in the NHS, and Product Adoption. Through this experience, AGA Nanotech will gain insights into market and clinical needs, competitive analysis, and tailored product development to treat biofilms, reduce AMR, and improve patient outcomes in the MSK space.
By the end of the accelerator, AGA Nanotech will pitch to the ORUK Investment Committee, with the opportunity to secure up to £100,000 in funding to further develop Battlestar™.